###begin article-title 0
###xml 86 87 86 87 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fn" rid="fn1">*</xref>
###xml 87 89 87 89 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fn" rid="fn2">S&#8414;</xref>
Eag1 Expression Interferes with Hypoxia Homeostasis and Induces Angiogenesis in Tumors*Sâƒž
###end article-title 0
###begin p 1
 To whom correspondence should be addressed. Tel.: 495513899643; Fax: 495513899644.
###end p 1
###begin p 2
###xml 0 15 0 15 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Author's Choice</italic>
Author's Choice
###end p 2
###begin p 3
 applies to Author Choice Articles
###end p 3
###begin p 4
###xml 354 361 354 361 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo</italic>
###xml 366 374 366 374 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro</italic>
Ether-a-go-go-1 (Eag1) is a CNS-localized voltage-gated potassium channel that is found ectopically expressed in a majority of extracranial solid tumors. While circumstantial evidence linking Eag1 to tumor biology has been well established, the mechanisms by which the channel contributes to tumor progression remain elusive. In this study, we have used in vivo and in vitro techniques to identify a candidate mechanism. A mutation that eliminates ion permeation fails to completely abolish xenograft tumor formation by transfected cells, indicating that Eag1 contributes to tumor progression independently of its primary function as an ion channel. Our data suggest that Eag1 interferes with the cellular mechanism for maintaining oxygen homeostasis, increasing HIF-1 activity, and thereby VEGF secretion and tumor vascularization.
###end p 4
###begin p 5
###xml 0 15 0 15 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Author's Choice</italic>
Author's Choice-Final version full access.
###end p 5
###begin p 6
###xml 141 154 141 154 <italic xmlns:xlink="http://www.w3.org/1999/xlink">advertisement</italic>
The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
###end p 6
###begin p 7
The on-line version of this article (available at ) contains supplemental information.
###end p 7
###begin p 8
###xml 22 23 22 23 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fn" rid="fn3">2</xref>
###xml 23 28 23 28 <italic xmlns:xlink="http://www.w3.org/1999/xlink">KCNH1</italic>
###xml 38 39 38 39 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref1">1</xref>
###xml 72 75 72 75 <italic xmlns:xlink="http://www.w3.org/1999/xlink">eag</italic>
###xml 162 163 162 163 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref2">2</xref>
###xml 165 166 165 166 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref3">3</xref>
###xml 238 239 238 239 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref4">4</xref>
###xml 241 242 241 242 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref5">5</xref>
###xml 431 432 431 432 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref5">5</xref>
###xml 525 526 525 526 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref6">6</xref>
###xml 527 528 527 528 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref8">8</xref>
###xml 550 551 550 551 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref9">9</xref>
###xml 552 554 552 554 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref11">11</xref>
###xml 633 635 633 635 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref12">12</xref>
###xml 708 716 708 716 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro</italic>
###xml 718 719 718 719 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref7">7</xref>
###xml 721 723 721 723 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref13">13</xref>
###xml 729 736 729 736 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo</italic>
###xml 738 740 738 740 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref14">14</xref>
###xml 148 151 <span type="species:ncbi:9860">Elk</span>
###xml 173 178 <span type="species:ncbi:9606">human</span>
Ether-a-go-go 1 (Eag1,2KCNH1, Kv10.1 (1)) is the founding member of the eag voltage-dependent potassium channel family, which also includes Erg and Elk channels (2, 3). The human Eag1 is normally expressed only within the nervous system (4, 5), yet ectopic Eag1 expression has been increasingly linked to oncogenesis and tumor progression. Overexpressing Eag1 induces a phenotype with characteristic features of tumorigenic cells (5). Additionally, Eag1 mRNA and its product have been detected in numerous cancer cell lines (6-8) and primary tumors (9-11). Finally, siRNA-mediated knockdown of Eag1 expression reduces proliferation (12), and the inhibition of channel function reduces tumor progression both in vitro (7, 13) and in vivo (14). Yet despite the clear involvement of Eag1 in proliferation and tumor progression, the mechanism of its transformative properties has remained a mystery.
###end p 8
###begin p 9
###xml 15 16 15 16 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 92 94 92 94 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref15">15</xref>
###xml 95 97 95 97 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref17">17</xref>
###xml 273 277 273 277 <italic xmlns:xlink="http://www.w3.org/1999/xlink">e.g.</italic>
###xml 284 286 284 286 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref18">18</xref>
###xml 287 289 287 289 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref20">20</xref>
###xml 522 524 522 524 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref15">15</xref>
###xml 525 527 525 527 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref17">17</xref>
###xml 529 531 529 531 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref21">21</xref>
Several other K+ channels have been implicated in tumor progression and cell proliferation (15-17). Different theories have attempted to explain the possible role of potassium channels in proliferation, all of which rely on the effects of increased potassium permeability (e.g. Refs. 18-20). Despite these efforts, a clear relationship between potassium permeation and tumor progression has yet to be established. In particular, the reason why only some channels can influence the behavior of tumor cells remains elusive (15-17, 21).
###end p 9
###begin p 10
###xml 535 539 535 539 <italic xmlns:xlink="http://www.w3.org/1999/xlink">e.g.</italic>
###xml 545 547 545 547 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref22">22</xref>
###xml 645 647 641 643 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref23">23</xref>
###xml 649 651 645 647 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref24">24</xref>
###xml 715 717 711 713 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref25">25</xref>
###xml 903 905 899 901 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref26">26</xref>
###xml 1012 1014 1008 1010 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref27">27</xref>
In this study, we investigated a possible interaction between Eag1 and signaling routes known to be relevant for tumor progression. The hypoxic intratumoral environment promotes the activation of hypoxia-inducible factor 1 (HIF-1), which is a key transcription factor influencing a broad spectrum of functions. Among them, neo-vascularization through transcriptional activation of vascular endothelial growth factor (VEGF) has become a promising target for cancer therapy as neoangiogenesis has a major influence on tumor progression (e.g. Ref. 22). In the presence of normal oxygen conditions, the regulated subunit of HIF-1 (HIF-1alpha; Refs. 23, 24) is rapidly degraded by the proteasome on an order of minutes (25) in an ubiquitin-dependent manner. The E3 ubiquitin ligase responsible for this process contains pVHL (von-Hippel-Lindau tumor suppressing factor), a well-established tumor suppressor (26). Previous reports show an influence of pVHL in the functional expression of Eag1 in neuroblastoma cells (27), which was interpreted as a sign for differentiation to a neuronal phenotype. We designed the present study to elucidate a possible cross-talk between Eag1 and the hypoxia homeostasis system.
###end p 10
###begin title 11
EXPERIMENTAL PROCEDURES
###end title 11
###begin p 12
###xml 0 12 0 12 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Cell Culture</italic>
###xml 455 456 454 455 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
Cell Culture-All parental cell lines were obtained from DSMZ (Germany) and maintained according to the instructions of the provider. Transient transfections were performed using Fugene (Roche Applied Science). Stable transfectants were selected and maintained using Zeocin (Calya, 3 mug/ml in culture medium). 24 h after transfection, transiently transfected cells were transferred to hypoxic conditions for 4 h. Culturing under hypoxia was performed by N2 injection in an oxygen-controlling chamber (Labotec).
###end p 12
###begin p 13
###xml 0 14 0 14 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Flow Cytometry</italic>
###xml 140 141 140 141 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 334 340 <span type="species:ncbi:9913">bovine</span>
###xml 524 530 <span type="species:ncbi:9913">bovine</span>
###xml 656 661 <span type="species:ncbi:10090">mouse</span>
Flow Cytometry-Cells were incubated for 20 h in the absence of selective pressure, washed twice with cold PBS, and fixed for 30 min with 4% p-formaldehyde at 4 degreesC. Fixed cells were scraped from the flask, washed three times, and permeabilized with 0.3% saponin for 15 min at room temperature. Cells were then incubated with 10% bovine serum albumin, 0.15% saponin for 15 min to block nonspecific binding, and incubated for 2 h at 4degreesC with HIF-1a antibody (AB463, BD Biosciences) diluted 1:100 in 0.1% saponin/2% bovine serum albumin in PBS (PBS-SB). Cells were washed three times with PBS-SB and then incubated 1.5 h with a Cy5-conjugated anti-mouse antibody diluted 1:5000 in PBS-SB. Cells were again washed three times and assessed for Cy5 fluorescence using a BD FACSAria flow cytometer (Becton Dickinson, Heidelberg, Germany) with 633-nm laser excitation. Forward and side scatter were used to detect and discard cell fragments and doublets. Data are presented as average fluorescence.
###end p 13
###begin p 14
###xml 0 9 0 9 <label xmlns:xlink="http://www.w3.org/1999/xlink">FIGURE 1.</label>
###xml 59 66 59 66 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo</italic>
###xml 9 92 9 92 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Block of Eag1 by astemizole inhibits tumor growth <italic>in vivo</italic> in an Eag1-dependent way.</bold>
###xml 286 287 281 282 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 365 366 360 361 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 369 370 364 365 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 9 658 9 643 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="15"><bold>Block of Eag1 by astemizole inhibits tumor growth <italic>in vivo</italic> in an Eag1-dependent way.</bold> Daily oral administration of astemizole (&#9633;) reduced the growth rate of xenograft tumors induced by implantation of Eag1-transfected CHO cells with respect to vehicle-treated controls (&#9675;) (<italic>A</italic>), but failed to inhibit the growth of tumors induced by wild-type CHO cells (<italic>B</italic>). <italic>C</italic>, breast cancer xenograft model cell line MDA-MB435S, which natively expresses Eag1, exhibits a reduction of tumor growth when animals were treated with astemizole. The extent of the astemizole effect was comparable with the well-established cytotoxic drug cyclophosphamide (&#9653;).</p>
###xml 9 658 9 643 <caption xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="15"><bold>Block of Eag1 by astemizole inhibits tumor growth <italic>in vivo</italic> in an Eag1-dependent way.</bold> Daily oral administration of astemizole (&#9633;) reduced the growth rate of xenograft tumors induced by implantation of Eag1-transfected CHO cells with respect to vehicle-treated controls (&#9675;) (<italic>A</italic>), but failed to inhibit the growth of tumors induced by wild-type CHO cells (<italic>B</italic>). <italic>C</italic>, breast cancer xenograft model cell line MDA-MB435S, which natively expresses Eag1, exhibits a reduction of tumor growth when animals were treated with astemizole. The extent of the astemizole effect was comparable with the well-established cytotoxic drug cyclophosphamide (&#9653;).</p></caption>
###xml 658 658 643 643 <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="zbc0020960000001"/>
###xml 0 658 0 643 <fig xmlns:xlink="http://www.w3.org/1999/xlink" position="float" id="fig1"><label>FIGURE 1.</label><caption><p textid="15"><bold>Block of Eag1 by astemizole inhibits tumor growth <italic>in vivo</italic> in an Eag1-dependent way.</bold> Daily oral administration of astemizole (&#9633;) reduced the growth rate of xenograft tumors induced by implantation of Eag1-transfected CHO cells with respect to vehicle-treated controls (&#9675;) (<italic>A</italic>), but failed to inhibit the growth of tumors induced by wild-type CHO cells (<italic>B</italic>). <italic>C</italic>, breast cancer xenograft model cell line MDA-MB435S, which natively expresses Eag1, exhibits a reduction of tumor growth when animals were treated with astemizole. The extent of the astemizole effect was comparable with the well-established cytotoxic drug cyclophosphamide (&#9653;).</p></caption><graphic xlink:href="zbc0020960000001"/></fig>
FIGURE 1.Block of Eag1 by astemizole inhibits tumor growth in vivo in an Eag1-dependent way. Daily oral administration of astemizole (square) reduced the growth rate of xenograft tumors induced by implantation of Eag1-transfected CHO cells with respect to vehicle-treated controls (o) (A), but failed to inhibit the growth of tumors induced by wild-type CHO cells (B). C, breast cancer xenograft model cell line MDA-MB435S, which natively expresses Eag1, exhibits a reduction of tumor growth when animals were treated with astemizole. The extent of the astemizole effect was comparable with the well-established cytotoxic drug cyclophosphamide (triangle up).
###end p 14
###begin p 15
###xml 50 57 50 57 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo</italic>
###xml 0 83 0 83 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Block of Eag1 by astemizole inhibits tumor growth <italic>in vivo</italic> in an Eag1-dependent way.</bold>
###xml 277 278 272 273 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 356 357 351 352 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 360 361 355 356 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
Block of Eag1 by astemizole inhibits tumor growth in vivo in an Eag1-dependent way. Daily oral administration of astemizole (square) reduced the growth rate of xenograft tumors induced by implantation of Eag1-transfected CHO cells with respect to vehicle-treated controls (o) (A), but failed to inhibit the growth of tumors induced by wild-type CHO cells (B). C, breast cancer xenograft model cell line MDA-MB435S, which natively expresses Eag1, exhibits a reduction of tumor growth when animals were treated with astemizole. The extent of the astemizole effect was comparable with the well-established cytotoxic drug cyclophosphamide (triangle up).
###end p 15
###begin p 16
###xml 0 9 0 9 <label xmlns:xlink="http://www.w3.org/1999/xlink">FIGURE 2.</label>
###xml 9 49 9 49 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Eag1-G440S-expressing cells form tumors.</bold>
###xml 49 50 49 50 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 106 107 106 107 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 126 127 126 127 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 144 145 144 145 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 176 177 176 177 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 285 286 285 286 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 295 296 295 296 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 331 332 331 332 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 352 353 352 353 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 367 368 367 368 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 387 388 387 388 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 475 479 475 479 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n.s.</italic>
###xml 502 503 502 503 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 9 512 9 512 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="17"><bold>Eag1-G440S-expressing cells form tumors.</bold><italic>A</italic>, tumor weight comparisons between xenografted Eag1-wt (<italic>n</italic> = 9), Eag1-G440S (<italic>n</italic> = 10), Eag2-wt (<italic>n</italic> = 10), or vector-transfected (<italic>n</italic> = 10) NIH3T3 cells. Eag1-G440S-expressing cells statistically equivalent tumors as Eag1-transfected cells (<italic>p</italic> = 0.3). <italic>B</italic>, CHO cells transfected with Eag1-(<italic>n</italic> = 16), Eag1-G440S (<italic>n</italic> = 16), Eag2-(<italic>n</italic> = 15), or vector (<italic>n</italic> = 5) show similar behavior, albeit G440S-expressing tumors are significantly smaller. <italic>n.s.</italic>, nonsignificant; ***, <italic>p</italic> &lt; 0.001.</p>
###xml 9 512 9 512 <caption xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="17"><bold>Eag1-G440S-expressing cells form tumors.</bold><italic>A</italic>, tumor weight comparisons between xenografted Eag1-wt (<italic>n</italic> = 9), Eag1-G440S (<italic>n</italic> = 10), Eag2-wt (<italic>n</italic> = 10), or vector-transfected (<italic>n</italic> = 10) NIH3T3 cells. Eag1-G440S-expressing cells statistically equivalent tumors as Eag1-transfected cells (<italic>p</italic> = 0.3). <italic>B</italic>, CHO cells transfected with Eag1-(<italic>n</italic> = 16), Eag1-G440S (<italic>n</italic> = 16), Eag2-(<italic>n</italic> = 15), or vector (<italic>n</italic> = 5) show similar behavior, albeit G440S-expressing tumors are significantly smaller. <italic>n.s.</italic>, nonsignificant; ***, <italic>p</italic> &lt; 0.001.</p></caption>
###xml 512 512 512 512 <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="zbc0020960000002"/>
###xml 0 512 0 512 <fig xmlns:xlink="http://www.w3.org/1999/xlink" position="float" id="fig2"><label>FIGURE 2.</label><caption><p textid="17"><bold>Eag1-G440S-expressing cells form tumors.</bold><italic>A</italic>, tumor weight comparisons between xenografted Eag1-wt (<italic>n</italic> = 9), Eag1-G440S (<italic>n</italic> = 10), Eag2-wt (<italic>n</italic> = 10), or vector-transfected (<italic>n</italic> = 10) NIH3T3 cells. Eag1-G440S-expressing cells statistically equivalent tumors as Eag1-transfected cells (<italic>p</italic> = 0.3). <italic>B</italic>, CHO cells transfected with Eag1-(<italic>n</italic> = 16), Eag1-G440S (<italic>n</italic> = 16), Eag2-(<italic>n</italic> = 15), or vector (<italic>n</italic> = 5) show similar behavior, albeit G440S-expressing tumors are significantly smaller. <italic>n.s.</italic>, nonsignificant; ***, <italic>p</italic> &lt; 0.001.</p></caption><graphic xlink:href="zbc0020960000002"/></fig>
FIGURE 2.Eag1-G440S-expressing cells form tumors.A, tumor weight comparisons between xenografted Eag1-wt (n = 9), Eag1-G440S (n = 10), Eag2-wt (n = 10), or vector-transfected (n = 10) NIH3T3 cells. Eag1-G440S-expressing cells statistically equivalent tumors as Eag1-transfected cells (p = 0.3). B, CHO cells transfected with Eag1-(n = 16), Eag1-G440S (n = 16), Eag2-(n = 15), or vector (n = 5) show similar behavior, albeit G440S-expressing tumors are significantly smaller. n.s., nonsignificant; ***, p < 0.001.
###end p 16
###begin p 17
###xml 0 40 0 40 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Eag1-G440S-expressing cells form tumors.</bold>
###xml 40 41 40 41 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 97 98 97 98 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 117 118 117 118 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 135 136 135 136 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 167 168 167 168 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 276 277 276 277 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 286 287 286 287 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 322 323 322 323 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 343 344 343 344 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 358 359 358 359 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 378 379 378 379 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 466 470 466 470 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n.s.</italic>
###xml 493 494 493 494 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
Eag1-G440S-expressing cells form tumors.A, tumor weight comparisons between xenografted Eag1-wt (n = 9), Eag1-G440S (n = 10), Eag2-wt (n = 10), or vector-transfected (n = 10) NIH3T3 cells. Eag1-G440S-expressing cells statistically equivalent tumors as Eag1-transfected cells (p = 0.3). B, CHO cells transfected with Eag1-(n = 16), Eag1-G440S (n = 16), Eag2-(n = 15), or vector (n = 5) show similar behavior, albeit G440S-expressing tumors are significantly smaller. n.s., nonsignificant; ***, p < 0.001.
###end p 17
###begin p 18
###xml 0 10 0 10 <italic xmlns:xlink="http://www.w3.org/1999/xlink">VEGF ELISA</italic>
###xml 124 125 124 125 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2</sup>
VEGF ELISA-Mock-transfected, Clone A, Clone B, and Clone C HEK293 cells were counted and plated at the same density in 25 cm2 flasks. Cells were cultured overnight with medium containing the selective agent Zeocin (3 mug/ml), after which the media was changed and cultured for 20 h without selection pressure. Cell culture supernatant was removed and centrifuged to remove cell particulates and detached cells, then assayed for secreted VEGF (Quantikine VEGF ELISA assay kit, R&D Systems). Cells in the flask were stained with propidium iodide and counted using a flow cytometer.
###end p 18
###begin p 19
###xml 0 16 0 16 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Luciferase Assay</italic>
Luciferase Assay-Mock-transfected and Clone A cells were counted and plated at the same density in 6-well plates. Cells were then transfected using Lipofectamine 2000 in Optimem with Bartrons HRE vector for 4 h, after which the medium was changed to normal growth medium. Luminescence was assayed using a Luciferase Reporter Gene Assay from Roche Applied Science.
###end p 19
###begin p 20
###xml 0 12 0 12 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Western Blot</italic>
###xml 62 63 58 59 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 92 93 88 89 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 168 169 164 165 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 271 272 267 268 <italic xmlns:xlink="http://www.w3.org/1999/xlink">g</italic>
Western Blot-For HIF1alpha detection, cells were lysed in 10 mm Tris-HCl pH 6.8, 1% SDS, 5 mm dithiothreitol, Protease Inhibitor Mixture (Roche Applied Science), and 8 m urea and to minimize HIF degradation, homogenized using an UltraTurrax device, centrifuged (14,000 x g 15 min), and the supernatant was used as total cell extract. Protein concentration was determined using BCA (Pierce).
###end p 20
###begin p 21
Protein extracts were separated by gradient SDS-PAGE (either 3-8 or 4-12%) and transferred to nitrocellulose membranes. Membranes were blocked with 0.1% casein (Roche Applied Science) and incubated with the corresponding antibody. Antibody against HIF1alpha (BD Transduction Laboratories) was used at 0.5-1 mug/ml overnight in a humidified chamber. After washing and incubation with appropriate peroxidase-labeled secondary antibody, blots were developed using Millipore Immobilon system. Signals were detected in a Bio-Rad Chem-Doc luminescence detection system.
###end p 21
###begin p 22
###xml 0 12 0 12 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Mouse Models</italic>
###xml 32 33 32 33 <sup xmlns:xlink="http://www.w3.org/1999/xlink">6</sup>
###xml 47 48 47 48 <sup xmlns:xlink="http://www.w3.org/1999/xlink">6</sup>
###xml 74 75 74 75 <sup xmlns:xlink="http://www.w3.org/1999/xlink">6</sup>
###xml 754 761 754 761 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ex vivo</italic>
###xml 0 5 <span type="species:ncbi:10090">Mouse</span>
###xml 133 137 <span type="species:ncbi:10090">mice</span>
Mouse Models-MDA-MB-435S (8 x 106), CHO (2 x 106), or NIH3T3 cells (6 x 106) were implanted into the flank of 8-week-old female scid mice (Taconic). End point experiments were carried out for 3 weeks. For tumor growth inhibition experiments, treatment started after the tumors reached a size of 2 mm in diameter, daily via an oral feeder. Astemizole (Sigma) was prepared as stock solution (50 mg/ml) in DMSO and diluted in phosphate-buffered saline prior to administration. As a positive control, 5 mg/kg cyclophosphamide (Sigma) was administered to the animals using the same protocol. Body weight and tumor size (using a caliper) were measured every 2 days. To minimize errors, the same operator always measured the tumors. Tumor weight was determined ex vivo at the end of the experiment.
###end p 22
###begin p 23
###xml 0 9 0 9 <label xmlns:xlink="http://www.w3.org/1999/xlink">FIGURE 3.</label>
###xml 9 66 9 66 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Eag1-expressing tumors display increased vascularization.</bold>
###xml 66 67 66 67 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 444 461 444 461 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Inset, arrowheads</italic>
###xml 547 558 546 557 <italic xmlns:xlink="http://www.w3.org/1999/xlink">white arrow</italic>
###xml 636 637 635 636 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref5">5</xref>
###xml 698 699 697 698 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 810 811 809 810 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 916 917 913 914 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 9 926 9 923 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="24"><bold>Eag1-expressing tumors display increased vascularization.</bold><italic>A</italic>, histological appearance of tumors induced by CHO cells in the presence or absence of Eag1 or Eag1 G440S expression. Sections from PFA-fixed and paraffin-embedded tumors from xenografted mock-transfected and Eag1-transfected CHO cells in SCID mice were immunostained for CD31 expression and counterstained with hematoxylin. Endothelial cells were identified by CD31 staining (<italic>Inset, arrowheads</italic>; scale bar, 50 &#956;m) Note the prominent necrosis in Eag1-wild type-expressing tumors (<italic>white arrow</italic>), which correlates with the previously described behavior of these implants (<xref ref-type="bibr" rid="ref5">5</xref>). Tumors of similar sizes were selected for representation. <italic>B</italic>, quantification of the surface occupied by CD31-positive capillaries in the three types of tumors depicted in <italic>A</italic>. Tumors expressing Eag1 and Eag1G440S showed significantly increased vascularization (mean &#177; S.E.; *, <italic>p</italic> &lt; 0.05).</p>
###xml 9 926 9 923 <caption xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="24"><bold>Eag1-expressing tumors display increased vascularization.</bold><italic>A</italic>, histological appearance of tumors induced by CHO cells in the presence or absence of Eag1 or Eag1 G440S expression. Sections from PFA-fixed and paraffin-embedded tumors from xenografted mock-transfected and Eag1-transfected CHO cells in SCID mice were immunostained for CD31 expression and counterstained with hematoxylin. Endothelial cells were identified by CD31 staining (<italic>Inset, arrowheads</italic>; scale bar, 50 &#956;m) Note the prominent necrosis in Eag1-wild type-expressing tumors (<italic>white arrow</italic>), which correlates with the previously described behavior of these implants (<xref ref-type="bibr" rid="ref5">5</xref>). Tumors of similar sizes were selected for representation. <italic>B</italic>, quantification of the surface occupied by CD31-positive capillaries in the three types of tumors depicted in <italic>A</italic>. Tumors expressing Eag1 and Eag1G440S showed significantly increased vascularization (mean &#177; S.E.; *, <italic>p</italic> &lt; 0.05).</p></caption>
###xml 926 926 923 923 <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="zbc0020960000003"/>
###xml 0 926 0 923 <fig xmlns:xlink="http://www.w3.org/1999/xlink" position="float" id="fig3"><label>FIGURE 3.</label><caption><p textid="24"><bold>Eag1-expressing tumors display increased vascularization.</bold><italic>A</italic>, histological appearance of tumors induced by CHO cells in the presence or absence of Eag1 or Eag1 G440S expression. Sections from PFA-fixed and paraffin-embedded tumors from xenografted mock-transfected and Eag1-transfected CHO cells in SCID mice were immunostained for CD31 expression and counterstained with hematoxylin. Endothelial cells were identified by CD31 staining (<italic>Inset, arrowheads</italic>; scale bar, 50 &#956;m) Note the prominent necrosis in Eag1-wild type-expressing tumors (<italic>white arrow</italic>), which correlates with the previously described behavior of these implants (<xref ref-type="bibr" rid="ref5">5</xref>). Tumors of similar sizes were selected for representation. <italic>B</italic>, quantification of the surface occupied by CD31-positive capillaries in the three types of tumors depicted in <italic>A</italic>. Tumors expressing Eag1 and Eag1G440S showed significantly increased vascularization (mean &#177; S.E.; *, <italic>p</italic> &lt; 0.05).</p></caption><graphic xlink:href="zbc0020960000003"/></fig>
###xml 311 315 <span type="species:ncbi:10090">mice</span>
FIGURE 3.Eag1-expressing tumors display increased vascularization.A, histological appearance of tumors induced by CHO cells in the presence or absence of Eag1 or Eag1 G440S expression. Sections from PFA-fixed and paraffin-embedded tumors from xenografted mock-transfected and Eag1-transfected CHO cells in SCID mice were immunostained for CD31 expression and counterstained with hematoxylin. Endothelial cells were identified by CD31 staining (Inset, arrowheads; scale bar, 50 mum) Note the prominent necrosis in Eag1-wild type-expressing tumors (white arrow), which correlates with the previously described behavior of these implants (5). Tumors of similar sizes were selected for representation. B, quantification of the surface occupied by CD31-positive capillaries in the three types of tumors depicted in A. Tumors expressing Eag1 and Eag1G440S showed significantly increased vascularization (mean +/- S.E.; *, p < 0.05).
###end p 23
###begin p 24
###xml 0 57 0 57 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Eag1-expressing tumors display increased vascularization.</bold>
###xml 57 58 57 58 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 435 452 435 452 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Inset, arrowheads</italic>
###xml 538 549 537 548 <italic xmlns:xlink="http://www.w3.org/1999/xlink">white arrow</italic>
###xml 627 628 626 627 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref5">5</xref>
###xml 689 690 688 689 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 801 802 800 801 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 907 908 904 905 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 302 306 <span type="species:ncbi:10090">mice</span>
Eag1-expressing tumors display increased vascularization.A, histological appearance of tumors induced by CHO cells in the presence or absence of Eag1 or Eag1 G440S expression. Sections from PFA-fixed and paraffin-embedded tumors from xenografted mock-transfected and Eag1-transfected CHO cells in SCID mice were immunostained for CD31 expression and counterstained with hematoxylin. Endothelial cells were identified by CD31 staining (Inset, arrowheads; scale bar, 50 mum) Note the prominent necrosis in Eag1-wild type-expressing tumors (white arrow), which correlates with the previously described behavior of these implants (5). Tumors of similar sizes were selected for representation. B, quantification of the surface occupied by CD31-positive capillaries in the three types of tumors depicted in A. Tumors expressing Eag1 and Eag1G440S showed significantly increased vascularization (mean +/- S.E.; *, p < 0.05).
###end p 24
###begin p 25
###xml 0 20 0 20 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Immunohistochemistry</italic>
###xml 211 212 211 212 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
Immunohistochemistry-Formalin-fixed and paraffin-embedded tumor sections were deparaffinized and rehydrated in a series of xylol and ethanol solutions. Antigen retrieval was performed in a microwave oven in 10 mm citrate buffer (pH 6.0) for 15 min. Slides were incubated overnight in a humidified chamber at 4 degreesC with anti CD34, anti VEGF receptor, anti-Factor VIII (all from Abcam) or anti-CD31 antibodies (Santa Cruz Biotechnology) and immunoreactivity was detected using the Envision Peroxidase System and DAB (DAKO). Sections were counterstained with hematoxylin and thereafter dehydrated and mounted in xylol-based mounting medium. The quantification of vascular surface was performed by a blinded operator using ImageJ software on 25 high power fields (400x) from each sample acquired.
###end p 25
###begin title 26
RESULTS
###end title 26
###begin p 27
###xml 0 72 0 72 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Open Channel Blockade of Eag1 Channels Reduces Tumor Progression in Vivo</italic>
###xml 220 228 220 228 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro</italic>
###xml 230 231 230 231 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref7">7</xref>
###xml 233 235 233 235 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref13">13</xref>
###xml 285 292 285 292 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo</italic>
###xml 727 728 727 728 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 721 728 721 728 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig1" ref-type="fig">Fig. 1<italic>A</italic></xref>
###xml 1094 1095 1094 1095 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 1088 1095 1088 1095 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig1" ref-type="fig">Fig. 1<italic>B</italic></xref>
###xml 345 349 <span type="species:ncbi:10090">mice</span>
Open Channel Blockade of Eag1 Channels Reduces Tumor Progression in Vivo-Because inhibition of Eag1 by the open channel blockers astemizole and imipramine has been reported to inhibit proliferation of several cell types in vitro (7, 13), we tested if similar effects could be observed in vivo. CHO cells expressing Eag1 were implanted into SCID mice and astemizole (50 mg/kg) administered daily via oral gavage once palpable tumors had developed. Astemizole was selected instead of imipramine as it does not pass the blood-brain barrier and should therefore have little effect on intracranial Eag1. Tumor growth induced by implantation of Eag1-expressing cells was clearly inhibited in the group treated with astemizole (Fig. 1A), similar to growth inhibition observed after treatment with the well-established cytotoxic drug cyclophosphamide (CPM) (applied at the maximal tolerable dose of 5 mg/kg). The antitumoral effect of astemizole can be at least partially attributed to Eag1 blockade, as no growth inhibition occurred after application of astemizole in wild-type CHO cell tumors (Fig. 1B).
###end p 27
###begin p 28
###xml 273 275 273 275 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref28">28</xref>
###xml 383 384 383 384 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 377 384 377 384 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig1" ref-type="fig">Fig. 1<italic>C</italic></xref>
###xml 511 518 511 518 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo</italic>
###xml 597 599 597 599 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref14">14</xref>
###xml 70 75 <span type="species:ncbi:9606">human</span>
We subsequently tested the effect of astemizole on the slowly growing human cancer xenograft model MDA-MB435S. This cell line expresses Eag1, but not HERG (a relative of Eag1 that is very effectively blocked by astemizole and has also been implicated in tumor progression (28)). Astemizole was again able to inhibit tumor progression nearly as effectively as cyclophosphamide (Fig. 1C) without noticeable toxic effects. These results indicate that reducing ion permeation through Eag1 reduces tumor progression in vivo, in good agreement with results reported using a specific anti-Eag1 antibody (14).
###end p 28
###begin p 29
###xml 0 95 0 95 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Eliminating Ion Permeation Does Not Abolish Tumor Formation by Xenografted NIH3T3 Cells in Vivo</italic>
###xml 424 431 424 431 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo</italic>
###xml 827 828 827 828 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref5">5</xref>
###xml 592 596 <span type="species:ncbi:10090">mice</span>
###xml 746 750 <span type="species:ncbi:10090">mice</span>
Eliminating Ion Permeation Does Not Abolish Tumor Formation by Xenografted NIH3T3 Cells in Vivo-This effect of astemizole may indicate that potassium permeation is required for Eag1 to favor tumor growth. If potassium permeation is the only feature of Eag1 channels relevant to tumor progression, elimination of ion permeation (through a point mutation in the pore region) should also abolish Eag1-induced tumor progression in vivo. For these experiments NIH3T3 and CHO cells were used as xenograft models. Wild-type or mock-transfected NIH3T3 cells induce no tumors when implanted into SCID mice, while Eag1-expressing cells do. Previous experiments demonstrated that tumors arising from the implantation of Eag1-transfected CHO cells into SCID mice are larger and more aggressive than those generated by wild-type CHO cells (5).
###end p 29
###begin p 30
###xml 111 112 111 112 <italic xmlns:xlink="http://www.w3.org/1999/xlink">G</italic>
###xml 241 243 241 243 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref29">29</xref>
###xml 355 362 355 362 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Xenopus</italic>
###xml 355 362 <span type="species:ncbi:8355">Xenopus</span>
Ion permeation was abolished by mutating a glycine residue in the signature sequence of the pore region (MTSVGFGN) to serine (G440S). This strategy has already been successfully applied to several ion channels, including Eag family members (29). To verify that the protein was synthesized and functional, RNA encoding the mutant channel was injected into Xenopus oocytes and electrophysiologically characterized. Although not permeating ions, correctly assembled and membrane resident channels should respond to membrane depolarizations by conformational changes that can be detected as capacitive currents (gating currents) by electrophysiological techniques. Expression of Eag1-G440S channels gave rise to gating currents with properties compatible with Eag1 (see supplemental information).
###end p 30
###begin p 31
###xml 374 375 374 375 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 368 375 368 375 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig2" ref-type="fig">Fig. 2<italic>A</italic></xref>
###xml 553 554 553 554 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 547 554 547 554 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig2" ref-type="fig">Fig. 2<italic>B</italic></xref>
###xml 125 129 <span type="species:ncbi:10090">mice</span>
###xml 589 593 <span type="species:ncbi:10090">mice</span>
Stable polyclonal NIH3T3 and CHO transfectants of the G440S mutant were implanted subcutaneously in the flank of female SCID mice. While previous experiments have shown that neither wild type nor vector-transfected NIH3T3 cells give rise to tumors in this system, G440S cells were found to produce tumors, albeit reduced in weight compared with wild-type Eag1 tumors (Fig. 2A). Therefore, ion permeation influences the oncogenic properties of Eag1, but it is not an absolute requirement. Comparable results were obtained when CHO cells were used (Fig. 2B) in two different strains of SCID mice (CB17 and scid/beige). G440S mutant channels induced tumors noticeably smaller than wild-type Eag1, but larger than mock- or Eag2-transfected cells. It is important to note that as an open channel blocker, astemizole locks the channel in the open conformation, while the G440S mutant can still undergo conformational transitions during gating.
###end p 31
###begin p 32
###xml 0 50 0 50 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Eag1-expressing Tumors Show Increased Angiogenesis</italic>
###xml 475 476 475 476 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 469 476 469 476 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig3" ref-type="fig">Fig. 3<italic>A</italic></xref>
###xml 554 555 554 555 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 548 555 548 555 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig3" ref-type="fig">Fig. 3<italic>A</italic></xref>
###xml 555 569 555 569 <italic xmlns:xlink="http://www.w3.org/1999/xlink">, arrows inset</italic>
###xml 831 832 831 832 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 825 832 825 832 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig3" ref-type="fig">Fig. 3<italic>A</italic></xref>
###xml 832 839 832 839 <italic xmlns:xlink="http://www.w3.org/1999/xlink">, right</italic>
Eag1-expressing Tumors Show Increased Angiogenesis-In contrast to NIH3T3 cells, non-transfected CHO cells also form sizeable tumors. This allows a direct comparison of the structure of tumors derived from Eag1-positive and Eag1-negative cells. Structures morphologically compatible with blood vessels were observed in tumors of similar volume arising from wild-type or mock-transfected cells, but the frequency of these was greatly increased in tumors expressing Eag1 (Fig. 3A). Positive staining with the well-established endothelial marker CD31 (Fig. 3A, arrows inset) indicates the presence of endothelial cells and thus identifies the structures as capillaries, indicating that Eag1 expression favors the formation of vascular structures in tumors. Eag1 G440S expression induced similar morphologies in xenograft tumors (Fig. 3A, right), indicating that increased vascularization does not require potassium permeation.
###end p 32
###begin p 33
###xml 102 106 102 106 <italic xmlns:xlink="http://www.w3.org/1999/xlink">i.e.</italic>
###xml 287 288 287 288 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 281 288 281 288 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig3" ref-type="fig">Fig. 3<italic>B</italic></xref>
Quantification of vascularization by measurement of CD31, VEGF-R, or Factor VIII-positive structures (i.e. capillaries) in 25 high power fields from at least two tumors of each type confirmed increased vascular structure surface area in both Eag1 and Eag1 G440S-expressing tumors (Fig. 3B).
###end p 33
###begin p 34
In light of these data, a possible explanation for the retained tumorigenic ability of mutant permeation-deficient Eag1 channels could be increased vascularization in these tumors. This observation further supports the idea that to some degree the transformative properties of Eag1 are independent of its canonical function as an ion channel and may be instead dependent on an interference with the cellular oxygen homeostasis system. More abundant vascularization would increase oxygen and nutrient supply to tumor cells and represent a selective growth advantage for Eag1-expressing cells.
###end p 34
###begin p 35
###xml 0 9 0 9 <label xmlns:xlink="http://www.w3.org/1999/xlink">FIGURE 4.</label>
###xml 9 58 9 58 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Eag1 expression induces increased VEGF secretion.</bold>
###xml 58 59 58 59 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 284 293 284 293 <italic xmlns:xlink="http://www.w3.org/1999/xlink">asterisks</italic>
###xml 358 359 358 359 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 381 382 381 382 <italic xmlns:xlink="http://www.w3.org/1999/xlink">t</italic>
###xml 394 395 394 395 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 405 406 405 406 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 530 531 530 531 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 552 553 552 553 <italic xmlns:xlink="http://www.w3.org/1999/xlink">t</italic>
###xml 9 581 9 581 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="36"><bold>Eag1 expression induces increased VEGF secretion.</bold><italic>A</italic>, VEGF is more abundant in the cell culture supernatant of polyclonal stably transfected NIH3T3 expressing the human Eag1 or Eag1 G440S. CHO cells expressing Eag1 also show increased VEGF secretion over mock-transfected. The <italic>asterisks</italic> indicate statistical significance by analysis of variance (3T3, <italic>p</italic> &lt; 0.05) or Student's <italic>t</italic> test (CHO, <italic>p</italic> &lt; 0.01). <italic>B</italic>, compared with mock-transfected cells, Eag1-expressing clones A, B, and C all exhibit greatly increased secretion of VEGF (<italic>p</italic> &lt; 0.0001, Student's <italic>t</italic> test) as measured by ELISA.</p>
###xml 9 581 9 581 <caption xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="36"><bold>Eag1 expression induces increased VEGF secretion.</bold><italic>A</italic>, VEGF is more abundant in the cell culture supernatant of polyclonal stably transfected NIH3T3 expressing the human Eag1 or Eag1 G440S. CHO cells expressing Eag1 also show increased VEGF secretion over mock-transfected. The <italic>asterisks</italic> indicate statistical significance by analysis of variance (3T3, <italic>p</italic> &lt; 0.05) or Student's <italic>t</italic> test (CHO, <italic>p</italic> &lt; 0.01). <italic>B</italic>, compared with mock-transfected cells, Eag1-expressing clones A, B, and C all exhibit greatly increased secretion of VEGF (<italic>p</italic> &lt; 0.0001, Student's <italic>t</italic> test) as measured by ELISA.</p></caption>
###xml 581 581 581 581 <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="zbc0020960000004"/>
###xml 0 581 0 581 <fig xmlns:xlink="http://www.w3.org/1999/xlink" position="float" id="fig4"><label>FIGURE 4.</label><caption><p textid="36"><bold>Eag1 expression induces increased VEGF secretion.</bold><italic>A</italic>, VEGF is more abundant in the cell culture supernatant of polyclonal stably transfected NIH3T3 expressing the human Eag1 or Eag1 G440S. CHO cells expressing Eag1 also show increased VEGF secretion over mock-transfected. The <italic>asterisks</italic> indicate statistical significance by analysis of variance (3T3, <italic>p</italic> &lt; 0.05) or Student's <italic>t</italic> test (CHO, <italic>p</italic> &lt; 0.01). <italic>B</italic>, compared with mock-transfected cells, Eag1-expressing clones A, B, and C all exhibit greatly increased secretion of VEGF (<italic>p</italic> &lt; 0.0001, Student's <italic>t</italic> test) as measured by ELISA.</p></caption><graphic xlink:href="zbc0020960000004"/></fig>
###xml 170 175 <span type="species:ncbi:9606">human</span>
FIGURE 4.Eag1 expression induces increased VEGF secretion.A, VEGF is more abundant in the cell culture supernatant of polyclonal stably transfected NIH3T3 expressing the human Eag1 or Eag1 G440S. CHO cells expressing Eag1 also show increased VEGF secretion over mock-transfected. The asterisks indicate statistical significance by analysis of variance (3T3, p < 0.05) or Student's t test (CHO, p < 0.01). B, compared with mock-transfected cells, Eag1-expressing clones A, B, and C all exhibit greatly increased secretion of VEGF (p < 0.0001, Student's t test) as measured by ELISA.
###end p 35
###begin p 36
###xml 0 49 0 49 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Eag1 expression induces increased VEGF secretion.</bold>
###xml 49 50 49 50 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 275 284 275 284 <italic xmlns:xlink="http://www.w3.org/1999/xlink">asterisks</italic>
###xml 349 350 349 350 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 372 373 372 373 <italic xmlns:xlink="http://www.w3.org/1999/xlink">t</italic>
###xml 385 386 385 386 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 396 397 396 397 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 521 522 521 522 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 543 544 543 544 <italic xmlns:xlink="http://www.w3.org/1999/xlink">t</italic>
###xml 161 166 <span type="species:ncbi:9606">human</span>
Eag1 expression induces increased VEGF secretion.A, VEGF is more abundant in the cell culture supernatant of polyclonal stably transfected NIH3T3 expressing the human Eag1 or Eag1 G440S. CHO cells expressing Eag1 also show increased VEGF secretion over mock-transfected. The asterisks indicate statistical significance by analysis of variance (3T3, p < 0.05) or Student's t test (CHO, p < 0.01). B, compared with mock-transfected cells, Eag1-expressing clones A, B, and C all exhibit greatly increased secretion of VEGF (p < 0.0001, Student's t test) as measured by ELISA.
###end p 36
###begin p 37
###xml 0 48 0 48 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Eag1 Expression Promotes VEGF Secretion in Vitro</italic>
###xml 130 132 130 132 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref30">30</xref>
###xml 134 136 134 136 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref31">31</xref>
###xml 587 588 587 588 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 581 588 581 588 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig4" ref-type="fig">Fig. 4<italic>A</italic></xref>
Eag1 Expression Promotes VEGF Secretion in Vitro-Among the many factors influencing angiogenesis, VEGF appears to be predominant (30, 31). VEGF has drawn intense attention in the field of oncology due both to its influence on tumor survival and to its potential use in cancer therapies. To test the possibility that the observed increase in vascularization of Eag1-expressing tumors correlates to an increase in secreted VEGF, we determined VEGF abundance in the culture supernatant of cells expressing Eag1. Determinations on the cell lines used for xenograft experiments showed (Fig. 4A) increased VEGF secretion in cells expressing both Eag1 and Eag1G440S.
###end p 37
###begin p 38
###xml 102 107 <span type="species:ncbi:9606">human</span>
###xml 182 187 <span type="species:ncbi:9606">human</span>
###xml 240 245 <span type="species:ncbi:9606">human</span>
Commercially available antibodies and kits for the determination of VEGF are normally targeted to the human factor. These kits provide much better sensitivity and reproducibility on human samples and so HEK293 cells were selected for their human origin and ease-of-use.
###end p 38
###begin p 39
###xml 0 9 0 9 <label xmlns:xlink="http://www.w3.org/1999/xlink">FIGURE 5.</label>
###xml 9 66 9 62 <bold xmlns:xlink="http://www.w3.org/1999/xlink">HIF-1&#945; protein is increased in Eag1-expressing cells.</bold>
###xml 66 67 62 63 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 303 304 291 292 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 322 323 310 311 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 345 346 333 334 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 439 440 423 424 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 567 568 551 552 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 587 588 571 572 <italic xmlns:xlink="http://www.w3.org/1999/xlink">D</italic>
###xml 683 684 663 664 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 687 688 667 668 <italic xmlns:xlink="http://www.w3.org/1999/xlink">E</italic>
###xml 728 729 708 709 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 852 854 832 834 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2.</sub>
###xml 854 858 834 838 <italic xmlns:xlink="http://www.w3.org/1999/xlink">*, p</italic>
###xml 871 872 851 852 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 9 880 9 860 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="40"><bold>HIF-1&#945; protein is increased in Eag1-expressing cells.</bold><italic>A</italic>, representative peak shift of HIF-1&#945; fluorescence in flow cytometry experiments using anti-HIF-1&#945; antibodies and Cy5.5-labeled secondary antibody on Eag1-transfected as compared with mock-transfected cells under normoxic (21% O<sub>2</sub>) or hypoxic (1% O<sub>2</sub> for 4 h) conditions. <italic>B</italic>, quantitative HIF-1&#945; fluorescence increase in Clones A, B, and C over mock-transfected. <italic>C</italic>, Eag1-expressing cells show increased HRE-dependent luciferase activity over mock-transfected cells in both untreated and CoCl<sub>2</sub>-treated cultures. <italic>D</italic>, HIF-1&#945; is more abundant in Eag1-transfected cells when incubated under mild hypoxia (5% O<sub>2</sub>). <italic>E</italic>, HRE activity is elicited by lower CoCl<sub>2</sub> concentrations in Eag1-expressing cells. Luciferase activity is represented normalized for activity in the absence of CoCl<sub>2.</sub><italic>*, p</italic> &lt; 0.05; **, <italic>p</italic> &lt; 0.01.</p>
###xml 9 880 9 860 <caption xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="40"><bold>HIF-1&#945; protein is increased in Eag1-expressing cells.</bold><italic>A</italic>, representative peak shift of HIF-1&#945; fluorescence in flow cytometry experiments using anti-HIF-1&#945; antibodies and Cy5.5-labeled secondary antibody on Eag1-transfected as compared with mock-transfected cells under normoxic (21% O<sub>2</sub>) or hypoxic (1% O<sub>2</sub> for 4 h) conditions. <italic>B</italic>, quantitative HIF-1&#945; fluorescence increase in Clones A, B, and C over mock-transfected. <italic>C</italic>, Eag1-expressing cells show increased HRE-dependent luciferase activity over mock-transfected cells in both untreated and CoCl<sub>2</sub>-treated cultures. <italic>D</italic>, HIF-1&#945; is more abundant in Eag1-transfected cells when incubated under mild hypoxia (5% O<sub>2</sub>). <italic>E</italic>, HRE activity is elicited by lower CoCl<sub>2</sub> concentrations in Eag1-expressing cells. Luciferase activity is represented normalized for activity in the absence of CoCl<sub>2.</sub><italic>*, p</italic> &lt; 0.05; **, <italic>p</italic> &lt; 0.01.</p></caption>
###xml 880 880 860 860 <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="zbc0020960000005"/>
###xml 0 880 0 860 <fig xmlns:xlink="http://www.w3.org/1999/xlink" position="float" id="fig5"><label>FIGURE 5.</label><caption><p textid="40"><bold>HIF-1&#945; protein is increased in Eag1-expressing cells.</bold><italic>A</italic>, representative peak shift of HIF-1&#945; fluorescence in flow cytometry experiments using anti-HIF-1&#945; antibodies and Cy5.5-labeled secondary antibody on Eag1-transfected as compared with mock-transfected cells under normoxic (21% O<sub>2</sub>) or hypoxic (1% O<sub>2</sub> for 4 h) conditions. <italic>B</italic>, quantitative HIF-1&#945; fluorescence increase in Clones A, B, and C over mock-transfected. <italic>C</italic>, Eag1-expressing cells show increased HRE-dependent luciferase activity over mock-transfected cells in both untreated and CoCl<sub>2</sub>-treated cultures. <italic>D</italic>, HIF-1&#945; is more abundant in Eag1-transfected cells when incubated under mild hypoxia (5% O<sub>2</sub>). <italic>E</italic>, HRE activity is elicited by lower CoCl<sub>2</sub> concentrations in Eag1-expressing cells. Luciferase activity is represented normalized for activity in the absence of CoCl<sub>2.</sub><italic>*, p</italic> &lt; 0.05; **, <italic>p</italic> &lt; 0.01.</p></caption><graphic xlink:href="zbc0020960000005"/></fig>
FIGURE 5.HIF-1alpha protein is increased in Eag1-expressing cells.A, representative peak shift of HIF-1alpha fluorescence in flow cytometry experiments using anti-HIF-1alpha antibodies and Cy5.5-labeled secondary antibody on Eag1-transfected as compared with mock-transfected cells under normoxic (21% O2) or hypoxic (1% O2 for 4 h) conditions. B, quantitative HIF-1alpha fluorescence increase in Clones A, B, and C over mock-transfected. C, Eag1-expressing cells show increased HRE-dependent luciferase activity over mock-transfected cells in both untreated and CoCl2-treated cultures. D, HIF-1alpha is more abundant in Eag1-transfected cells when incubated under mild hypoxia (5% O2). E, HRE activity is elicited by lower CoCl2 concentrations in Eag1-expressing cells. Luciferase activity is represented normalized for activity in the absence of CoCl2.*, p < 0.05; **, p < 0.01.
###end p 39
###begin p 40
###xml 0 57 0 53 <bold xmlns:xlink="http://www.w3.org/1999/xlink">HIF-1&#945; protein is increased in Eag1-expressing cells.</bold>
###xml 57 58 53 54 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 294 295 282 283 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 313 314 301 302 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 336 337 324 325 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 430 431 414 415 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 558 559 542 543 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 578 579 562 563 <italic xmlns:xlink="http://www.w3.org/1999/xlink">D</italic>
###xml 674 675 654 655 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 678 679 658 659 <italic xmlns:xlink="http://www.w3.org/1999/xlink">E</italic>
###xml 719 720 699 700 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 843 845 823 825 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2.</sub>
###xml 845 849 825 829 <italic xmlns:xlink="http://www.w3.org/1999/xlink">*, p</italic>
###xml 862 863 842 843 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
HIF-1alpha protein is increased in Eag1-expressing cells.A, representative peak shift of HIF-1alpha fluorescence in flow cytometry experiments using anti-HIF-1alpha antibodies and Cy5.5-labeled secondary antibody on Eag1-transfected as compared with mock-transfected cells under normoxic (21% O2) or hypoxic (1% O2 for 4 h) conditions. B, quantitative HIF-1alpha fluorescence increase in Clones A, B, and C over mock-transfected. C, Eag1-expressing cells show increased HRE-dependent luciferase activity over mock-transfected cells in both untreated and CoCl2-treated cultures. D, HIF-1alpha is more abundant in Eag1-transfected cells when incubated under mild hypoxia (5% O2). E, HRE activity is elicited by lower CoCl2 concentrations in Eag1-expressing cells. Luciferase activity is represented normalized for activity in the absence of CoCl2.*, p < 0.05; **, p < 0.01.
###end p 40
###begin p 41
###xml 345 346 345 346 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 339 346 339 346 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig4" ref-type="fig">Fig. 4<italic>B</italic></xref>
To discard artifacts due to genomic insertion, VEGF secretion was measured in three independent clones of the HEK293 cell line stably expressing Eag1 by ELISA (Clones A, B, and C) and compared with mock-transfected cells. All three Eag1-expressing cell lines were found to secrete significantly more VEGF than the non-transfected control (Fig. 4B). This VEGF increase correlates with the observed vascularization increase of Eag1-expressing tumors.
###end p 41
###begin p 42
###xml 0 20 0 20 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Eag1 Increases HIF-1</italic>
###xml 571 572 555 556 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 565 572 549 556 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig5" ref-type="fig">Fig. 5<italic>A</italic></xref>
###xml 810 811 790 791 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 804 811 784 791 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig5" ref-type="fig">Fig. 5<italic>B</italic></xref>
Eag1 Increases HIF-1alpha-The most likely candidate for the up-regulation of VEGF in Eag1-transfected cells and increase in vascularization in Eag1-expressing tumors is a functional increase of HIF-1. To investigate this possibility, HIF-1alpha expression was examined using flow cytometry for HEK293 Clones A, B, and C with an anti-HIF-1alpha antibody and a fluorescently labeled (Cy5.5) secondary antibody. Compared with mock-transfected cells, the fluorescence histogram of each clone showed a rightward shift, consistent with an increase in HIF-1alpha content (Fig. 5A). The peak shift induced by Eag1 expression was much less intense under hypoxia. Quantitative comparison of the mean HIF-1alpha fluorescence values calculated for each cell line and normalized to mock-transfected cells is shown in Fig. 5B. Each clone displayed independently of oxygen concentration and culture conditions (data not shown) modest but significantly increased HIF-1alpha fluorescence over mock-transfected cells.
###end p 42
###begin p 43
###xml 367 369 363 365 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref32">32</xref>
###xml 523 524 519 520 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 517 524 513 520 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig5" ref-type="fig">Fig. 5<italic>C</italic></xref>
###xml 524 536 520 532 <italic xmlns:xlink="http://www.w3.org/1999/xlink">, left panel</italic>
###xml 580 581 575 576 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 586 587 581 582 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 757 758 752 753 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 751 758 746 753 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig5" ref-type="fig">Fig. 5<italic>C</italic></xref>
###xml 758 765 753 760 <italic xmlns:xlink="http://www.w3.org/1999/xlink">, right</italic>
To test whether this increase of HIF-1alpha can have functional implications, we studied the activity of a HIF-1 responsive promoter. This was done by determining the luciferase activity in both control and Eag1-expressing HEK293 cells transiently transfected with a reporter vector encoding luciferase under control of the HRE of 6-phosphofructo-2-kinase (HRE-Luc) (32). Eag1-expressing cells (Clone A) maintained in normoxia showed a dramatic increase in luciferase activity compared with control cells after 48 h (Fig. 5C, left panel). Mock-hypoxic conditions induced by 200 mum CoCl2 treatment for 18 h resulted in luciferase activity increases in both control and transfected cells, while maintaining a similar increase in Eag1-expressing cells (Fig. 5C, right).
###end p 43
###begin p 44
###xml 81 82 81 82 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 177 178 173 174 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 191 192 187 188 <italic xmlns:xlink="http://www.w3.org/1999/xlink">D</italic>
###xml 185 192 181 188 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig5" ref-type="fig">Fig. 5<italic>D</italic></xref>
###xml 536 537 524 525 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
Western blot analysis of cell extracts from cultures exposed to either 21 or 1% O2 did not consistently show increases in HIF-1alpha protein content. However, mild hypoxia (5% O2, 4 h; Fig. 5D) induced a clear increase in HIF1alpha abundance in Eag1-expressing cells. Because no increase in HIF was observed under normoxia, it is unlikely that the differences in HIF abundance can be attributed to an artifactual local hypoxia. A comparable elevation in HIF1alpha content was observed in transiently transfected cells when hypoxia (7% O2, 4 h) was applied 24 h after transfection (not shown).
###end p 44
###begin p 45
###xml 305 307 297 299 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2+</sup>
###xml 446 448 434 436 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2+</sup>
###xml 456 457 444 445 <italic xmlns:xlink="http://www.w3.org/1999/xlink">E</italic>
###xml 450 457 438 445 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig5" ref-type="fig">Fig. 5<italic>E</italic></xref>
These results indicate that Eag1 expression induces an increase in HIF1alpha under mild hypoxia, which could reflect a shift on the threshold of the HIF-1 system. To investigate this, we determined the increase of HIF-1alpha activity over basal conditions in the presence of different concentrations of Co2+ in Eag1 and mock-transfected cells. Eag1-expressing cells were found to induce increased HIF-1alpha activity at lower concentrations of Co2+ (Fig. 5E). This finding could be interpreted as the result of interference of Eag1 with the HIF-1alpha control pathway. Altogether, these results suggest a causal relationship between the functional increase in HIF-1alpha and the increase of VEGF secretion observed in Eag1-expressing cell lines.
###end p 45
###begin title 46
DISCUSSION
###end title 46
###begin p 47
###xml 109 110 109 110 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref5">5</xref>
###xml 112 113 112 113 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref7">7</xref>
###xml 114 116 114 116 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref12">12</xref>
###xml 118 120 118 120 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref21">21</xref>
Despite several studies implicating ectopic expression of Eag1 in many cancer cell lines and primary tumors (5, 7-12, 21), information regarding the mechanism of Eag1 contribution to oncogenesis has thus far remained unclear. Using a broad spectrum of techniques, we present evidence indicating that the oncogenic potential of Eag1 is partly independent of its primary physiological function as an ion channel. We also show a functional up-regulation of HIF-1 and VEGF in Eag1-expressing cells. We propose a possible mechanism by which Eag1 could favor tumor progression through increased angiogenesis under the characteristic hypoxia of tumor microenvironment.
###end p 47
###begin p 48
###xml 76 84 76 84 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro</italic>
###xml 202 209 202 209 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo</italic>
###xml 442 444 442 444 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref14">14</xref>
###xml 875 885 875 885 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Drosophila</italic>
###xml 891 893 891 893 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref33">33</xref>
###xml 929 931 929 931 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref34">34</xref>
###xml 875 885 <span type="species:ncbi:7227">Drosophila</span>
Eag1 inhibition has proven efficacious in reducing tumor cell proliferation in vitro. However, a point mutation in Eag1 that abolishes ion permeation failed to eliminate tumor induction in NIH3T3 cells in vivo. This observation strongly suggests that ion permeation is not essential for the tumor promoting activity of Eag1. While at first seeming incompatible with the reported ability of a functional antibody to inhibit tumor progression (14), this result would be explained if the conformational changes normally accompanying gating constitute a significant part of the Eag1 tumorigenic signal; a blocked channel would be locked in a defined conformational state, whereas the mutant channel would still be able to undergo conformational changes. Therefore, properties of Eag1 other than ion permeation must influence cellular signaling, as has recently been proposed for Drosophila eag (33) and other voltage-gated channels (34).
###end p 48
###begin p 49
###xml 73 74 73 74 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref9">9</xref>
###xml 76 78 76 78 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref10">10</xref>
###xml 532 534 532 534 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref35">35</xref>
###xml 615 637 615 637 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Caenorhabditis elegans</italic>
###xml 704 706 704 706 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref36">36</xref>
###xml 615 637 <span type="species:ncbi:6239">Caenorhabditis elegans</span>
The very high frequency of ectopic expression of Eag1 in primary tumors (9, 10) indicates that Eag1 expression confers a selective advantage to tumor cells under conditions that are common to the majority of neoplasms. Such a common condition could be hypoxia. The major immediate consequence of hypoxia is HIF-1 up-regulation, which is widely accepted as a hallmark of cancer physiology, both from our understanding of the tumor microenvironment and the role of HIF-1 target genes in cell proliferation, survival and angiogenesis (35). Interestingly, mutations of both Eag1 and HIF prolyl-hydroxylase orthologs in Caenorhabditis elegans result in a similar egg-laying defect phenotype (reviewed in Ref. 36).
###end p 49
###begin p 50
###xml 548 550 548 550 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref37">37</xref>
###xml 560 566 560 566 <italic xmlns:xlink="http://www.w3.org/1999/xlink">et al.</italic>
###xml 568 570 568 570 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref27">27</xref>
The observed increase in HIF-1 activity in Eag1-expressing cells represents a novel explanation for the oncogenic potential of Eag1. The ectopic expression of Eag1 could thus have far reaching effects, as the increased secretion of growth factors and angiogenic-signaling molecules such as VEGF would have lasting effects within the local tumor microenvironment. Recently it has been reported that the related channel HERG also influences VEGF secretion in glioblastoma cell lines, although the mechanism by which this is achieved remains unclear (37). Murata et al. (27) described a negative correlation between pVHL and functional Eag1 expression. It is tempting to speculate that this interaction between the factor in charge of controlling the levels of HIF1 and Eag1 underlies the observed increase in HIF1 under mild hypoxia in Eag1-expressing cells, although this hypothesis requires direct testing.
###end p 50
###begin p 51
###xml 245 249 245 249 <italic xmlns:xlink="http://www.w3.org/1999/xlink">e.g.</italic>
###xml 256 258 256 258 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref38">38</xref>
###xml 260 262 260 262 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref39">39</xref>
In summary, we have observed in this study a novel non-canonical contribution of an ion channel to tumor formation. While non-canonical protein functions have been proposed as relevant for the phenotypic changes induced in heterologous systems (e.g. Refs. 38, 39), the evidence presented in this report supports their role in native systems as well.
###end p 51
###begin title 52
Supplementary Material
###end title 52
###begin title 53
[Supplemental Data]
###end title 53
###begin p 54
We thank D. A. Brown (UCL), D. Katschinski (University Gottingen), and F. Melchior (University Gottingen) for helpful suggestions, R. Bartrons, and D. Katchinski for the HRE reporter vectors, F. Mello de Queiroz and C. Kleinert for help in some experiments, S. Smith for assistance with editing the manuscript, and V. Diaz-Salamanca for excellent technical assistance.
###end p 54
###begin p 55
The abbreviations used are: Eag, ether-a-go-go; PBS, phosphate-buffered saline; VEGF, vascular endothelial growth factor; ELISA, enzyme-linked immunosorbent assay; HIF, hypoxia-inducible factor.
###end p 55

